Daewoong Pharma

Daewoong Pharma maintains a debt-to-equity ratio of 0.82, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.24, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited excess. Free cash flow stands at 43,567,135,350 KRW, which is relatively low compared to its operating cash flow of 149,205,466,390 KRW, indicating that capital expenditures are consuming a significant portion of operating cash. Profitability metrics show a return on equity (ROE) of 19.47% and a return on assets (ROA) of 8.29%, both of which are strong indicators of efficient capital utilization and asset management. These figures are in line with the typical performance of pharmaceutical companies, which often benefit from high-margin product lines and strong R&D pipelines. The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no material geographic diversification beyond South Korea. This concentration increases exposure to domestic regulatory and economic conditions, which could affect revenue stability. Looking ahead, Daewoong Pharma is expected to maintain a stable revenue trajectory, supported by its existing product portfolio and ongoing R&D initiatives. However, the company's capital expenditures have been negative, indicating a reduction in investment in new facilities or equipment, which may signal a focus on cost control or a shift in strategic priorities. Risk factors include the company's net cash position, which is negative after subtracting total debt, and the potential for dilution, although the risk is currently assessed as low. The company has not issued additional shares recently, and there is no indication of imminent dilutive events. Recent filings and transcripts do not highlight any major corporate events or strategic shifts. The company's focus remains on its core pharmaceutical business, with no significant new ventures or partnerships disclosed in the latest available data.